On January 8, 2020 Helix BioPharma Corp. (TSX: "HBP") ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, reported it has been selected to present at the Biotech Showcase Conference on Tuesday, January 14, 2020 at 11:00am (PT) at Hilton San Francisco Union Square (Press release, Helix BioPharma, JAN 8, 2020, View Source [SID1234553138]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Biotech Showcase Conference, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

During the conference, Helix will discuss its current development programs and opportunities for partnership. Helix will also update clinical progress on L-DOS47, its lead candidate for the treatment of non-squamous non-small cell lung cancer and pancreatic cancer.

"We are making excellent progress with our various DOS47 clinical initiatives," said Dr. Heman Chao, Helix’s Chief Executive Officer. "I look forward to updating everyone with our progress, especially our new pancreatic cancer study where we recently commenced patient dosing."